Customized phage therapies to eradicate
harmful bacteria in chronic diseases
Positive Phase 1 cosmetic clinical study results of BX001 in acne-prone skin reported; planned advance to Phase 2 study with readout expected in the second quarter of 2021. Initial BX002 Phase 1 clinical study readout in inflammatory bowel disease expected in the fourth quarter of 2020
BiomX Inc. announced that the Company will host a conference call and live audio webcast on Thursday, May 14, 2020, at 8:00 a.m. ET to report first quarter 2020 financial results and provide a corporate update.
Will hold its 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”) on June 3, 2020 at 9:00 a.m. Eastern Time. In light of public health concerns regarding the COVID-19 pandemic, the 2020 Annual Meeting will be held solely by remote communication, in a virtual-only format.